Why the study?
Does valsartan improve outcomes in patients with hypertension, post-myocardial infarction, or heart failure?
Does valsartan improve outcomes in patients with hypertension, post-myocardial infarction, or heart failure?
Valsartan is an effective ARB for managing hypertension and provides significant mortality and morbidity benefits in patients with heart failure or post-MI left ventricular dysfunction.
Valsartan (Diovan) is a widely use angiotensin receptor blocker that prevents angiotensin II from binding to the subtype 1 receptor. Stimulation of the subtype 1 receptor is believed to mediate many of the deleterious effects accompanied by increased angiotensin II levels. Valsartan is effective in the treatment of hypertension, alone and in combination with hydrochlorothiazide. Valsartan is similarly as effective as angiotensin-converting enzyme (ACE) blockers following myocardial infarction accompanied with left ventricular dysfunction, and/or heart failure. For the treatment of congestive heart failure with left ventricular dysfunction, valsartan offers a reduction in mortality in patients not able to tolerate an ACE inhibitor and in combination with an ACE inhibitor, valsartan reduces morbidity (hospitalization for heart failure).
No takes yet. Share an insight, caveat, or question.
Køber et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: